- BioMarin’s first-quarter earnings per share (EPS) surpassed estimates at $0.95, compared to $0.71 expected, and $0.46 last year.
- Revenue reached $745 million, marking a 15% increase year-over-year, surpassing the estimated $737 million.
- Vimizim revenue decreased by 2.4% to $188 million, falling short of the $193.9 million estimate.
- Naglazyme revenue increased by 8% to $114 million, exceeding the estimated $112 million.
- Kuvan revenue dropped 30% to $25 million, still surpassing the estimated $23.5 million.
- Palynziq revenue grew 23% to $93 million, just under the $95.1 million estimate.
- Voxzogo revenue jumped 40% to $214 million, slightly above the $211 million estimate.
- Aldurazyme revenue rose 39% to $49 million, significantly above the $38.5 million estimate.
- BioMarin expects Voxzogo revenues to be more weighted towards the second half of 2025 due to dynamic market factors outside the U.S.
- Alexander Hardy, President and CEO, highlighted the high demand for BioMarin’s innovative medicines fueling strong revenue growth and profitability.
- The investment community shows strong support with 23 buy ratings, 6 holds, and no sell ratings for BioMarin’s stock.
Biomarin Pharmaceutical on Smartkarma
In the realm of analyst coverage on Smartkarma, independent analysts from Baptista Research have provided insightful reports on Biomarin Pharmaceutical. One report titled “BioMarin Pharmaceutical: Expansion of VOXZOGO & Enzyme Replacement Therapy Growth Propelling Our ‘Buy’ Rating!” commended the company for its strong financial performance in the fourth quarter and full year of 2024. Biomarin recorded an impressive 18% year-over-year revenue growth, hitting $2.85 billion for the year, largely driven by the success of VOXZOGO in treating achondroplasia, which saw a remarkable 56% revenue increase.
Another report by Baptista Research, titled “BioMarin Pharmaceutical Inc.: Enhancement of Enzyme Replacement Therapy (ERT) Portfolio,” highlighted the company’s robust performance in the third quarter of 2024. Biomarin achieved record revenue of $746 million, marking a 28% growth from the previous year, with VOXZOGO sales soaring by 50%. This growth was attributed to expanded market reach in the U.S. and new geographical expansions. The analysts at Baptista Research lean bullish on Biomarin Pharmaceutical, recognizing its advancements in therapy portfolios and revenue growth.
A look at Biomarin Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Biomarin Pharmaceutical shows a promising long-term outlook. With a strong score of 5 for Growth, the company is expected to expand and evolve its product line successfully in the future. Additionally, Biomarin received solid scores of 4 for Resilience and Momentum, indicating its ability to withstand challenges and maintain positive market momentum.
Although Biomarin scored low in the Dividend category with a score of 1, the company’s overall outlook remains positive. Its value score of 3 suggests that investors may find Biomarin to be a solid investment choice. Overall, Biomarin Pharmaceutical Inc., known for developing therapeutic enzyme products and products for lysosomal storage diseases, seems well-positioned for long-term growth and success in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
